Compositions and methods of use for antibodies of c-Met
First Claim
Patent Images
1. An isolated human or humanized antibody or functional fragment thereof comprising an antigen-binding region that is specific for target protein c-Met, wherein the antibody or functional fragment thereof binds to c-Met, and wherein the sequence of the antibody or functional fragment thereof comprises:
- the sequences of CDR1, CDR2 and CDR3 of heavy chain 4687, wherein the sequences of CDR1, CDR2, and CDR3 of heavy chain 4687 are residues 26-35, 50-65, and 98-102, respectively, of SEQ ID NO;
58; and
the sequences of CDR1, CDR2, and CDR3 of light chain 5097, wherein the sequences of CDR1, CDR2, and CDR3 of light chain 5097 are residues 24-39, 55-61, and 94-100 of SEQ ID NO;
37.
3 Assignments
0 Petitions
Accused Products
Abstract
Antibodies and fragments that bind to the protein target c-Met, particularly to epitopes located in the c-Met extracellular domain, are provided, as are methods of use of the antibodies and kits, for treating an unwanted cell, in particular, a cell associated with a c-Met-related condition such as a cancer, a metastasis, or an inflammatory condition.
31 Citations
31 Claims
-
1. An isolated human or humanized antibody or functional fragment thereof comprising an antigen-binding region that is specific for target protein c-Met, wherein the antibody or functional fragment thereof binds to c-Met, and wherein the sequence of the antibody or functional fragment thereof comprises:
-
the sequences of CDR1, CDR2 and CDR3 of heavy chain 4687, wherein the sequences of CDR1, CDR2, and CDR3 of heavy chain 4687 are residues 26-35, 50-65, and 98-102, respectively, of SEQ ID NO;
58; andthe sequences of CDR1, CDR2, and CDR3 of light chain 5097, wherein the sequences of CDR1, CDR2, and CDR3 of light chain 5097 are residues 24-39, 55-61, and 94-100 of SEQ ID NO;
37. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)
-
-
10. An isolated amino acid sequence that binds to and is specific for target protein c-Met comprising CDR1, CDR2 and CDR3 sequences of the heavy and light chains of an antigen-binding region that is specific for target protein c-Met, wherein the CDR1, CDR2 and CDR3 of the heavy and light chains are encoded by nucleotides 78-105, 150-195, and 294-306, respectively, of SEQ ID NO:
- 24 and nucleotides 72-117, 165-183, and 282-300, respectively, of SEQ ID NO;
7. - View Dependent Claims (11, 12)
- 24 and nucleotides 72-117, 165-183, and 282-300, respectively, of SEQ ID NO;
-
13. An isolated amino acid sequence comprising CDR1, CDR2 and CDR3 sequences of a light chain and a heavy chain of an antigen-binding region that is specific for target protein c-Met, wherein the CDR sequences from the heavy chain are:
-
CDR1=GGTFSSYAIS (residues 26-35 of SEQ ID NO;
58)CDR2=GIDPFGTANYAQKFQG (residues 50-65 of SEQ ID NO;
58)CDR3=VYQDV (residues 98-102 of SEQ ID NO;
58), and the CDR sequences from the light chain are;CDR1=RSSQSILYGINNNFLG (residues 24-39 of SEQ ID NO;
37)CDR2=WASTRES (residues 55-61 of SEQ ID NO;
37)CDR3=QQYAFGW (residues 94-100 of SEQ ID NO;
37).
-
Specification